Physician profile
Jefferson Trupp
NPI 1871552638
$1,671.49
in general payments reported to CMS, 2019-2025
33 companies · $883 in 2025
The $883 reported for 2025 was more than what 82% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $112 · 2021: $112 · 2022: $233 · 2023: $73.41 · 2024: $75.75 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $282.03 | 2020-2025 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $221.48 | 2019-2025 | |
| Novocure INC. | $203.71 | 2020-2025 | Optune Lua (Novottf-200t), Optune Gio |
| Merck Sharp & Dohme LLC | $115.19 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $73.39 | 2022-2025 | Enhertu |
| Stemline Therapeutics INC. | $68.00 | 2025 | Orserdu |
| Csl Behring | $61.85 | 2025 | Hizentra |
| Varian Medical Systems, INC. | $43.74 | 2020 | |
| Eisai INC. | $43.36 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.46 | 2023-2025 | |
| Progenics Pharmaceuticals, INC. | $42.26 | 2022 | |
| Incyte Corporation | $41.11 | 2025 | Jakafi |
| Genzyme Corporation | $40.62 | 2022-2025 | |
| Pfizer INC. | $36.08 | 2021-2025 | |
| Morphosys, US INC. | $28.70 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $27.79 | 2025 | Tecentriq |
| Lilly USA, LLC | $24.16 | 2019 | |
| Pharmaessentia USA Corporation | $23.55 | 2025 | Besremi |
| Karyopharm Therapeutics INC. | $22.19 | 2024 | Xpovio |
| Beigene USA, INC. | $22.06 | 2024 | Brukinsa |
| Sumitomo Pharma America, INC. | $21.53 | 2025 | Orgovyx |
| Beone Medicines USA, INC. | $20.10 | 2025 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $19.86 | 2025 | Monoferric |
| Tesaro, INC. | $18.12 | 2019 | |
| Taiho Oncology, INC. | $18.00 | 2025 | |
| Adc Therapeutics America, INC. | $16.80 | 2023 | |
| Amgen INC. | $16.66 | 2019 | |
| Janssen Biotech, INC. | $16.26 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.35 | 2019 | |
| Myovant Sciences INC. | $14.67 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.40 | 2020 | |
| Iovance Biotherapeutics, INC. | $9.71 | 2025 | Amtagvi |
| Brainlab, INC. | $9.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jefferson Trupp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.